Mitchell Smith, DO
Allergy & Immunology · Greenwood, INNPI 1700101102
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,071 of the $32,622 with a category attached, or 61.5%. 36 manufacturers reported payments, led by Novartis at 55.4% of the total. 2025 is the largest year on record at $19,467, 3.4 times the $5,796 reported in 2019.
Across 296 payments — averaging $110.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$18K
- Dermira, Inc.$6K
- Sanofi$3K
- AstraZeneca$2K
- Genentech USA, Inc.$1K
- GSK$691
- plus $3K from 30 others
Across 12 payments — averaging $32,702 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$372K
- AstraZeneca$21K
What the payments were for
- Consulting fees$20,07162%
- Speaking & faculty fees$2,3127%
- Travel & lodging$3,89312%
- Food & beverage$6,25619%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $18,076 |
| Dermira, Inc. | 3 | $5,534 |
| Sanofi | 13 | $2,701 |
| AstraZeneca | 68 | $1,517 |
| Genentech USA, Inc. | 6 | $1,448 |
| GSK | 52 | $691 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $300 |
| Regeneron Healthcare Solutions, Inc. | 12 | $261 |
| Grifols USA, LLC | 6 | $195 |
| CSL Behring | 10 | $186 |
| Galderma Laboratories, L.p. | 4 | $178 |
| Blueprint Medicines Corporation | 3 | $175 |
| Amgen | 6 | $125 |
| AbbVie | 6 | $120 |
| Biocryst US Sales Co., LLC | 3 | $111 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $96 |
| Pharming Healthcare, Inc. | 4 | $95 |
| Pfizer | 5 | $94 |
| Octapharma USA, Inc. | 4 | $93 |
| Kaleo, Inc. | 4 | $77 |
| Ionis Pharmaceuticals, Inc. | 2 | $73 |
| Boehringer Ingelheim | 5 | $71 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Verona Pharma, Inc. | 2 | $47 |
| Incyte Corporation | 2 | $44 |
| Bio Products Laboratory USA, Inc. | 3 | $44 |
| LEO Pharma Inc. | 3 | $43 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| Alk-abello, Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Hospira, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $15 |
| Circassia Inc. | 1 | $13 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,622 in reported general payments places this provider in the 80th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 25 | $105,979 |
| Dupixent PenDupilumab | 24 | $91,102 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $64,846 |
| Spiriva RespimatTiotropium Bromide | 36 | $24,927 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $24,247 |
| Epinephrine | 91 | $15,204 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $7,977 |
| Ipratropium Bromide | 147 | $4,090 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $3,533 |
| Montelukast Sodium | 323 | $3,033 |
| Azelastine Hcl | 80 | $2,701 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $1,770 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,322 |
| Fluticasone Propionate | 26 | $543 |
| Famotidine | 28 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $691 | $89,093108 claims |
| Boehringer IngelheimSpiriva Respimat | $71 | $24,92736 claims |
| Hikma Pharmaceuticals USAEpinephrine | $24 | $15,20491 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Greenwood
- John DuplantierGreenwood$6K
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
- Ketan ShethLafayette$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.